137 related articles for article (PubMed ID: 36716925)
1. Soluble guanylate cyclase agonist, isoliquiritigenin attenuates renal damage and aortic calcification in a rat model of chronic kidney failure.
Atteia HH; Alamri ES; Sirag N; Zidan NS; Aljohani RH; Alzahrani S; Arafa MH; Mohammad NS; Asker ME; Zaitone SA; Sakr AT
Life Sci; 2023 Mar; 317():121460. PubMed ID: 36716925
[TBL] [Abstract][Full Text] [Related]
2. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
[TBL] [Abstract][Full Text] [Related]
3. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
4. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway.
Chen L; Zhou X; Deng Y; Yang Y; Chen X; Chen Q; Liu Y; Fu X; Kwan HY; You Y; Jin W; Zhao X
J Ethnopharmacol; 2023 Jan; 300():115705. PubMed ID: 36099983
[TBL] [Abstract][Full Text] [Related]
5. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
Bénardeau A; Kahnert A; Schomber T; Meyer J; Pavkovic M; Kretschmer A; Lawrenz B; Hartmann E; Mathar I; Hueser J; Kraehling JR; Eitner F; Hahn MG; Stasch JP; Sandner P
Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2363-2379. PubMed ID: 34550407
[TBL] [Abstract][Full Text] [Related]
6. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
7. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
Stehle D; Xu MZ; Schomber T; Hahn MG; Schweda F; Feil S; Kraehling JR; Eitner F; Patzak A; Sandner P; Feil R; Bénardeau A
Br J Pharmacol; 2022 Jun; 179(11):2476-2489. PubMed ID: 34096053
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
[TBL] [Abstract][Full Text] [Related]
10. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
El-Sehemy A; Chang AC; Azad AK; Gupta N; Xu Z; Steed H; Karsan A; Fu Y
Cell Signal; 2013 Dec; 25(12):2780-7. PubMed ID: 24041655
[TBL] [Abstract][Full Text] [Related]
11. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
12. Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Cuez T; Schunck WH; Manthati VL; Falck JR; Malik KU
Nitric Oxide; 2013 Sep; 33():18-41. PubMed ID: 23684565
[TBL] [Abstract][Full Text] [Related]
13. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2006 Jan; 290(1):F167-76. PubMed ID: 16048904
[TBL] [Abstract][Full Text] [Related]
14. Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase.
Monfort P; Muñoz MD; Kosenko E; Felipo V
J Neurosci; 2002 Dec; 22(23):10116-22. PubMed ID: 12451112
[TBL] [Abstract][Full Text] [Related]
15. The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system.
Correia SS; Liu G; Jacobson S; Bernier SG; Tobin JV; Schwartzkopf CD; Atwater E; Lonie E; Rivers S; Carvalho A; Germano P; Tang K; Iyengar RR; Currie MG; Hadcock JR; Winrow CJ; Jones JE
J Neuroinflammation; 2021 Sep; 18(1):213. PubMed ID: 34537066
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
17. C-type natriuretic peptide-induced relaxation through cGMP-dependent protein kinase and SERCA activation is impaired in two kidney-one clip rat aorta.
Pernomian L; do Prado AF; Silva BR; de Paula TD; Grando MD; Bendhack LM
Life Sci; 2021 May; 272():119223. PubMed ID: 33610574
[TBL] [Abstract][Full Text] [Related]
18. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
Hoffmann LS; Kretschmer A; Lawrenz B; Hocher B; Stasch JP
PLoS One; 2015; 10(12):e0145048. PubMed ID: 26717150
[TBL] [Abstract][Full Text] [Related]
19. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.
Mujoo K; Sharin VG; Martin E; Choi BK; Sloan C; Nikonoff LE; Kots AY; Murad F
Nitric Oxide; 2010 Jan; 22(1):43-50. PubMed ID: 19948239
[TBL] [Abstract][Full Text] [Related]
20. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
